Axol Bioscience Ltd. generated a human iPSC-derived retinal organoid model carrying the RHO-P23H mutation to investigate disease-associated phenotypes in a physiologically relevant human system.

Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, specializing in the manufacture of high-performance iPSC-derived cells and the delivery of industry-leading laboratory services. With over a decade of expertise, Axol partners with global pharmaceutical companies, contract research organizations (CROs), biotechnology firms, start-ups, and academic institutions to advance the use of iPSC-based models in drug discovery and disease research. We operate across five key areas, neuroscience (including ALS, Alzheimer’s, Huntington’s, Parkinson’s, neuroinflammation), pain & sensation, ophthalmology (Dry-AMD, ophthal-inflammation), dermatology, and cardiovascular. Axol offers scalable solutions including iPSC banking, reprogramming, gene editing, cell manufacturing, and quality control. The company is committed to closing the translational gap, developing physiologically relevant in vitro systems that improve consistency and relevance in human disease modeling and compound testing. Axol is recognized for its scientific excellence, transparent collaboration, and rigorous quality standards, with manufacturing operations certified to ISO 9001:2015.